Status:
UNKNOWN
Evaluation the Effect of Acetyl-L-carnitine in Patients With Mild Cognitive Impairment Accompanied With Chronic Cerebrovascular Disease
Lead Sponsor:
Hanmi Pharmaceutical Company Limited
Conditions:
Mild Cognitive Impairment
Eligibility:
All Genders
55-85 years
Phase:
PHASE4
Brief Summary
The purpose of this study is to evaluate the efficacy of Acetyl-L-carnitine in patient with Mild Cognitive Impairment associated with chronic cerebrovascular disease.
Eligibility Criteria
Inclusion
- Age between 55 and 85 years old
- Patients with chronic cerebrovascular disease, who have modified Fazekas scale grade 2 \~ 3
- Patients wtih a diagnosis of MCI
- MOCA-K of 23 or less
- Patients who provided a signed written informed consent form
Exclusion
- Patiens who are uneducated or illiterate
- Patiens previously treated with dementia
- Patients who received a nootropic agent or thyroid hormone within 4 weeks of visit 1
- Patients with cognitive impairment due to diseases other than cerebrovascular disease
- Patients with severe depression, schizophrenia, alcoholism, and drug dependence
Key Trial Info
Start Date :
January 26 2016
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 30 2020
Estimated Enrollment :
636 Patients enrolled
Trial Details
Trial ID
NCT04346862
Start Date
January 26 2016
End Date
June 30 2020
Last Update
April 21 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Catholic Kwandong University International St. Mary'S Hospital
Incheon, South Korea